Canaccord cuts Ionis stock price target on trial miss to $95

Canaccord cut Ionis Pharmaceuticals’ price target to $95 from $110 while keeping a Buy rating after Wainua (ATTR-CM) failed its Phase 3 primary endpoint for cardiovascular mortality and recurrent cardiovascular events. The stock fell to $64.27 from $84.46 on the setback, and Canaccord removed ATTR-CM royalty revenue from its model (while noting the drug remains on the market for ATTR-PN). Ionis said 2026 guidance is unchanged and it still expects cash-flow breakeven in 2028, but multiple firms reduced price targets to the low-$90s range despite generally favorable ratings.

Analysis

This is less a single-program miss than a re-rating event for Ionis’ partner economics. The market will likely haircut the probability-weighted value of the ATTR-CM royalty stream far more than management’s near-term guidance suggests, because late-stage cardiovascular assets are valued on optionality and durability, not just current sales. The key second-order winner is the incumbent standard-of-care franchise at PFE: stronger-than-expected performance from the baseline therapy raises the evidentiary bar for every follow-on entrant, which can slow switching and extend share longevity.

Near term, the stock can stay under pressure for days as systematic biotech holders de-risk binary execution risk. Over 1-3 months, the August cardiology data readout is the real catalyst; if the monotherapy subgroup is not clean enough to support a differentiated label or commercial thesis, the market may effectively zero out much of the ATTR-CM upside. Over 6-18 months, the question becomes whether wholly-owned assets can replace the lost present value; if they do not, the current drawdown may be the start of a lower valuation regime rather than a one-off gap.

The contrarian view is that consensus may be overreacting to a partner-asset failure as though it were a balance-sheet event. If Ionis can truly keep 2026 guidance intact and maintain its path to cash-flow breakeven, there is an argument for a tactical mean reversion trade once the initial forced selling clears. The falsifier is simple: any indication that the ATTR setback spills into broader pipeline confidence, or that management quietly de-risks future royalty assumptions, would argue the thesis is still deteriorating.

Key Decisions for Investors

• Short IONS on strength into the next 1-3 sessions, using rallies toward the post-gap breakdown area as entry; cover if management reiterates 2026 guidance with no further royalty/model cuts and the stock reclaims the gap.
• Relative-value trade: long PFE / short IONS for 1-3 months to express the view that the incumbent ATTR standard-of-care gains persistence while Ionis absorbs the valuation reset.
• Do not chase a broad biotech hedge here; this looks name-specific. Use IONS as a single-name volatility event, not a sector hedge, unless August ESC data turns the miss into a platform-wide concern.
• Watch item, not outright long: if IONS stabilizes above the low-$60s after the analyst downgrades and management quantifies replacement value from Tryngolza, consider covering shorts and reassessing for a tactical bounce trade.
• Falsifier alert: if August data supports the monotherapy subgroup strongly enough to preserve label or commercial optionality, the current selloff is likely overdone and the short should be reduced quickly.